ArticleFrontiers in medicine2026
A disulfide-bridged single-stranded DNA nanotube for co-delivery of siRNA and chemotherapeutics in ovarian cancer therapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Using DNA nanotechnology, we designed a disulfide-bridged single-stranded DNA nanotube (SS-DNT) functionalized with external aptamers for targeting, and encapsulating chemotherapeutic agents internally to induce apoptosis in cancer cells. Methods: The SS-DNT itself and the siRNA attachment points are linked via disulfide bonds, which can be fully cleaved in the intracellular glutathione (GSH) environment of tumors, thereby enhancing the release efficiency of the drug and siRNA. This SS-DNT offers a cost-effective synthesis process and high efficiency in payload release. Results: The SS-DNT exhibited efficient payload release, potent cytotoxicity, and significant tumor growth inhibition, with no detectable systemic toxicity in normal cells. Discussion: With its cost-effective synthesis, efficient siRNA and drug co-delivery, and demonstrated therapeutic efficacy, this DNA nanodevice represents a promising platform for precision cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.